DrugPatentWatch Database Preview
LENVIMA Drug Profile
When do Lenvima patents expire, and when can generic versions of Lenvima launch?
This drug has one hundred and seven patent family members in thirty countries.
The generic ingredient in LENVIMA is lenvatinib mesylate. One supplier is listed for this compound. Additional details are available on the lenvatinib mesylate profile page.
Summary for LENVIMA
| International Patents: | 107 |
| US Patents: | 3 |
| Applicants: | 1 |
| NDAs: | 1 |
| Suppliers / Packagers: | 1 |
| Bulk Api Vendors: | 61 |
| Clinical Trials: | 9 |
| Patent Applications: | 74 |
| Drug Prices: | see details |
| DailyMed Link: | LENVIMA at DailyMed |
Pharmacology for LENVIMA
| Drug Class | Kinase Inhibitor |
| Mechanism of Action | Receptor Tyrosine Kinase Inhibitors |
Synonyms for LENVIMA
| 4-(3-chloro-4-(3-cyclopropylureido)phenoxy)-7-methoxyquinoline-6-carboxamide |
| 4-(3-Chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide |
| 4-(3-chloro-4-(N'-cyclopropylureido)phenoxy)-7-methoxyquinoline-6-carboxamide |
| 4-[3-chloranyl-4-(cyclopropylcarbamoylamino)phenoxy]-7-methoxy-quinoline-6-carboxamide |
| 4-[3-Chloro-4-(cyclopropylaminocarbonyl)aminophenoxy]-7-methoxy-6-quinolinecarboxamide |
| 4-[3-chloro-4-(cyclopropylcarbamoylamino)phenoxy]-7-methoxy-quinoline-6-carboxamide |
| 4-[3-chloro-4-(cyclopropylcarbamoylamino)phenoxy]-7-methoxyquinoline-6-carboxamide |
| 4-[3-chloro-4-[[(cyclopropylamino)-oxomethyl]amino]phenoxy]-7-methoxy-6-quinolinecarboxamide |
| 4-{3-Chloro-4-[(Cyclopropylcarbamoyl)amino]phenoxy}-7-Methoxyquinoline-6-Carboxamide |
| 417716-92-8 |
| 4CA-0485 |
| 716C928 |
| A1-04306 |
| A825653 |
| ABP000863 |
| AC-25047 |
| AK175809 |
| AKOS025401742 |
| AN-6642 |
| AOB87766 |
| AS-16203 |
| BC252209 |
| BCP9000633 |
| BCPP000247 |
| BDBM50331094 |
| CHEBI:85994 |
| CHEMBL1289601 |
| CS-0109 |
| CTK1D4875 |
| D09919 |
| D0R0FO |
| DB-070219 |
| DB09078 |
| DTXSID50194605 |
| E 7080 |
| E-7080 |
| E-7080, E7080 |
| E7080 |
| E7080 (Lenvatinib) |
| E7080, E 7080 |
| E7080/E-7080 |
| EE083865G2 |
| ER-203492-00 |
| EX-A249 |
| FT-0700727 |
| GTPL7426 |
| HE068062 |
| HE342379 |
| HMS3244A07 |
| HMS3244A08 |
| HMS3244B07 |
| HMS3654A14 |
| HY-10981 |
| J-513372 |
| KB-78118 |
| Kisplyx |
| KS-00000638 |
| Lenvatinib |
| Lenvatinib (E7080) |
| Lenvatinib (USAN/INN) |
| Lenvatinib [USAN:INN] |
| Lenvatinib mesilate |
| Lenvatinib; E7080 |
| LenvatinibE7080) |
| LEV |
| MFCD16038644 |
| MLS006011239 |
| MolPort-009-679-469 |
| NCGC00263198-01 |
| QCR-115 |
| RS0099 |
| s1164 |
| SC-87813 |
| SCHEMBL864638 |
| SMR004702999 |
| SYN1038 |
| UNII-EE083865G2 |
| WOSKHXYHFSIKNG-UHFFFAOYSA-N |
| ZINC3816292 |
US Patents and Regulatory Information for LENVIMA
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Eisai Inc | LENVIMA | lenvatinib mesylate | CAPSULE;ORAL | 206947-001 | Feb 13, 2015 | RX | Yes | No | ➤ Sign Up | ➤ Sign Up | ➤ Sign Up | ||||
| Eisai Inc | LENVIMA | lenvatinib mesylate | CAPSULE;ORAL | 206947-002 | Feb 13, 2015 | RX | Yes | Yes | ➤ Sign Up | ➤ Sign Up | ➤ Sign Up | ||||
| Eisai Inc | LENVIMA | lenvatinib mesylate | CAPSULE;ORAL | 206947-001 | Feb 13, 2015 | RX | Yes | No | ➤ Sign Up | ➤ Sign Up | ➤ Sign Up | ||||
| Eisai Inc | LENVIMA | lenvatinib mesylate | CAPSULE;ORAL | 206947-002 | Feb 13, 2015 | RX | Yes | Yes | ➤ Sign Up | ➤ Sign Up | ➤ Sign Up | ||||
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
Non-Orange Book US Patents for LENVIMA
For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.
The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.
| Patent No. | Title | Estimated Patent Expiration |
|---|---|---|
| 8,372,981 | Nitrogen-containing aromatic derivatives | ➤ Sign Up |
| 7,612,092 | Nitrogen-containing aromatic derivatives | ➤ Sign Up |
| 7,973,160 | Nitrogen-containing aromatic derivatives | ➤ Sign Up |
| Patent No. | Title | Estimated Patent Expiration |
International Patents for LENVIMA
Supplementary Protection Certificates for LENVIMA
| Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|
| 90053-3 | Sweden | ➤ Sign Up | PRODUCT NAME: LENVATINIB OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF OR A HYDRATE THEREOF; REG. NO/DATE: EU/1/15/1002 20150601 |
| 858 | Luxembourg | ➤ Sign Up | PRODUCT NAME: LENVATINIB, OU UN DE SES SELS PHARMACEUTIQUEMENT ACCEPTABLES OU UN HYDRATE DE CELUI-CI |
| 15/050 | Ireland | ➤ Sign Up | PRODUCT NAME: LENVATINIB OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF OR A HYDRATE THEREOF; REGISTRATION NO/DATE: EU/1/15/1002/001-/002 20150528 |
| 2015 00053 | Denmark | ➤ Sign Up | PRODUCT NAME: LENVATINIB, ELLER ET FARMAKOLOGISK ACCEPTABELT SALT DERAF ELLER ET HYDRAT DERAF, HERUNDER LENVATINIB MESILAT; REG. NO/DATE: EU/1/15/1002/001-002 20150601 |
| Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
